Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL

Leukemia

Volumn 17, Issue 4, 2003, Pages 691-699

  Schiffer, C A ^a   Hehlmann, R ^b   Larson, R ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

CML; IFN ; Imatinib; Ph+ ALL; SCT

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTHRACYCLINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IMATINIB; METHOTREXATE; NUCLEOSIDE ANALOG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TROXACITABINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALGORITHM; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; FLUID RETENTION; GENETIC DISORDER; HUMAN; METHODOLOGY; NAUSEA AND VOMITING; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 0037399322     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402879     Document Type: Article

References (73)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1497.
2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446.
4. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998; 91: 1810-1819.
5. Anonymous. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid Leukemia Trialists' Collaborative Group. Br J Haematol 2000; 110: 573-576.
6. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR,, Anderson J, Bennett C et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517-1536.
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-abl positive cells. Nat Med 1996; 2: 561-566.
8. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
10. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
11. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
12. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49-61.
13. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
14. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732-1738.
15. van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
16. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122: 254-261.
17. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-229.
18. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
19. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
20. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
21. Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998-1005.
22. Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000; 18: 1533-1538.
23. Duba HC, Hilbe W, Mehringer A, Erdel M, Thaler J, Utermann G. Hypermetaphase and interphase fluorescence in situ hybridisation for monitoring of remission status in Philadelphia chromosome positive chronic myeloid leukaemia. Int J Oncol 2000; 17: 1245-1249.
24. Tamura S, Saheki K, Takatsuka H, Wada H, Fujimori Y, Okamoto T et al. Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies. Ann Hematol 2000; 79: 622-626.
25. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
26. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
27. Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM et al. Quantitative molecular methods to monitor the response of CML patients to interferon-alpha. Bone Marrow Transplant 1996; 17 (Suppl 3): S41-S44.
28. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts vK et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
29. Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999; 13: 957.
30. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
31. Hochhaus A, Reiter A, Skladny H, Reichert A, Saussele S, Hehlmann R. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res 1998; 144: 36-45.
32. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62-66.
33. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039-2042.
34. Druker B for the IRIS (International Randomized IFN vs STI571) Study Group. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN)+cytarabine as initial therapy for patients with CML: results of a randomized study. Proc Am Soc Clin Oncol 2002; 21: 1a (Abstract).
35. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997; 89: 1616.
36. The Italian Cooperative Study Group on Myeloid Leukemia. Long-term follow-up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia The Italian The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998; 92: 1541-1548.
37. Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998; 12: 31-80.
38. Mughal TI, Goldman JM. Chronic myeloid leukaemia: a therapeutic challenge. Ann Oncol 1995; 6: 637.
39. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
40. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087.
41. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the Procedure. Blood 1999; 94: 3668-3677.
42. Brunstein CG, McGlave PB. The biology and treatment of chronic myelogenous leukemia. Oncology (Huntingt) 2001; 15: 23-31.
43. Baron F, Frere P, Fillet G, Beguin Y. Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica 2001; 86: 993-994.
44. Wassmann B, Klein SA, Scheuring U, Pfeifer H, Martin H, Gschaidmeier H et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 721-724.
45. Kantarjian H, O'Brien S, Cortes J, Giralt S, Rios M, Shan J et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 299: 100.
46. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111: 6-17.
47. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
48. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219-2225.
49. Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001; 98: 3205-3211.
50. Margolis J, Borrello I, Flinn IW. New approaches to treating malignances with stem cell transplantation. Semin Oncol 2000; 27: 524-530.
51. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579.
52. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL et al. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67: 302.
53. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319.
54. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
55. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190.
56. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosinetriphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemiaor Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472.
57. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99: 10700.
58. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-91.
59. Sawyers CL. Research on resistance to cancer drug Gleevec. Science 2001; 294: 1834.
60. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996; 100: 555-570.
61. Schiffer CA. Acute myeloid leukemia in adults: where do we go from here. Cancer Chemother Pharmacol 2001; 48 (Suppl 1): S45-S52.
62. Dann EJ, Anastasi J, Larson RA. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol 1998; 16: 1498-1504.
63. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632.
64. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001; 19: 762-771.
65. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-413.
66. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyl transferase inhibitors. Curr Opin Oncol 2001; 13: 470-476.
67. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068.
68. Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931-3939.
69. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80: 2983-2990.
70. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV, Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196-199.
71. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen in, adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547.
72. Snyder DS. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2000; 6: 597.
73. Ottmann OG, Druker Bj, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger M, Schiffer CA, Baccarini M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien S. A phase II trial of imatinib in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 2002; 100: 1965.